Clinical Trial Update: PARP Inhibition for Gliomas (PI-4G or π4g) [Phase 2]

View source ↗

Summary

Phase 2 trial of a PARP inhibitor for gliomas was terminated, with results posted in 2024, evaluating recurrent glioblastoma, recurrent astrocytoma, and related…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioblastoma
• Glioma
• Oligodendroglioma

Drugs mentioned

• PI-4G (π4g) PARP inhibitor (PI-4G)

Snippet

Sponsor: University of Oklahoma | Conditions: Recurrent Glioblastoma, Recurrent Astrocytoma | Phase 2 | Status: TERMINATED | Results posted: 2024-11-06